findmyKOL

Valerie Harvey, MD

Basic profile

Dermatology

ORCID↗NPI↗
✓ Full record
RegionNewport News, VA · SoutheastSpecialtyDermatologyFocusDermatology
Active KOLEmergingfindmyKOL type: RegionalLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH funding2013–2016

Valerie Harvey is a Dermatology physician. OpenAlex indexes 53 publications with 915 citations (h-index 13).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
53publications

Distinct works indexed by OpenAlex, matched via ORCID.

915citations

Total citations across indexed works.

13h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
29companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2013–2016

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

860 Omni Blvd Ste 112
Newport News, VA 236064430

Telephone

757-232-8856

Registry record last updated 21 Jul 2022.

View the NPPES registry record

Industry payments

29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    27.5%
    Corticosteroid27.5%
    Clobetasol Propionate63%Hydrocortisone29%Betamethasone Dipropionate8%
    Part D≥80 patients
  • Anti-infectives

    27.2%
    Azole Antifungal12.7%
    Ketoconazole100%
    Part D≥74 patients
    Tetracycline-class Drug6.3%
    Doxycycline Hyclate100%
    Part D≥24 patients

    + 3 more classes in this area

  • Dermatology

    24.8%
    Corticosteroid15.2%
    Triamcinolone Acetonide79%Triamcinolone acetonide22%
    Part D + Part B≥73 patients
    Interleukin-4 Receptor alpha Antagonist4.1%
    Dupixent Pen67%Dupixent Syringe33%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 2013–2016 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”